P0106 - Buspiron like anxiolytic or panicogenic factor at patients suffering from agoraphobia with panic disorder

Abstract

Buspiron is non-benzodiazepine anxiolytic and it was the first alternative for benzodiazepins(Sramek,2002).

It was mostly used for the treatment of generalized anxiety disorders(GAD), but the efficacy was 7,5% in clinical trials.The most frequent reason for no-efficacy were psychosocial and environmental factors(Haller,2004,1).

The biological basis of panic attacks is hypersenzitivity of autonomic nerve system (Tanay,2001), as a praecipitating factor is hyperventilation(Eric,1991,1996) or using the stimulating factors(like cigarets, coffee, alcohol, drugs).

It is supposed, that anxiety disorders are caused by stress.We have more and more patients by years and incorrect diagnostic process and treatmentcan lead to chronification.We used hydroxizin from no-benzodiazepin anxiolytics alone or in combination with short-time dynamicpsychotherapy (Ignjatovic,1998)or with cognitive-behavioral psychotherapy with control breathing during acute phase(Ignjatovičova,2003)for the treatment anxiety disorders.

We sellected 8 patients suffering from agoraphobia with panic disorder from our out-patient practice.These patients were treated by buspiron, but treatment was non-effective.We used Hamilton scale for anxiety at beginning and every patients had HAMA more than 18 points.The goal of our study was decreasing HAMA score more than 50% and reductino of panic attacks more than 50% after finishing treatment by buspiron, and using control breathing.

7 patients from 8 patients have no panic attack during acute phase of treatment .They stopped use buspiron and starting with control breathing.

From our casuistics we supposed, that incorect treatment by buspiron like common anxiolytics can increase anxiety, praecipitate panic attacks and increase depressive symptoms at patients suffering from agoraphobia with panic disorder.